Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and meta-analysis

BACKGROUND: Lung cancer is a major cause of death among patients, and non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers in many countries. AIM: To evaluate the clinical benefit (CB) of COX-2 inhibitors in patients with advanced NSCLC using systematic review. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yu-Qiong, Long, Xiang, Han, Ming, Huang, Ming-Qiang, Lu, Jia-Fa, Sun, Xue-Dong, Han, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Systematic Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829738/
https://www.ncbi.nlm.nih.gov/pubmed/33553396
http://dx.doi.org/10.12998/wjcc.v9.i3.581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829738/
https://www.ncbi.nlm.nih.gov/pubmed/33553396
http://dx.doi.org/10.12998/wjcc.v9.i3.581

Ejemplares similares